If that was the case at this time when M&A activity is high and people are paying a lot of value for both NASDAQ and ASX listed biotechs why would they get only a regional deal with a $10m upfront for a Phase 3 ready asset at the back of randomised placebo controlled Phase 2 trial data, with payments highly back ended as majority of milestones are commercial on sales.. I take it this was the best deal on the table .. does not reflect people are falling over to buy the company. Next catalyst will be once Acadia starts a Phase 3 which is a year away. Unlikely stock going to do much in the interim till then. I think the BP report states well all the upside to their valuation.
If that was the case at this time when M&A activity is high and...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$16.15 |
Change
-0.940(5.50%) |
Mkt cap ! $2.064B | |||
| Open | High | Low | Value | Volume |
| $15.04 | $16.33 | $14.65 | $25.91M | 1.638M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 125 | $16.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.20 | 1500 | 1 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |